Biotest

Biotest P/B

Delisted

The P/B (Price-to-Book Ratio) of Biotest (BIO.DE) as of Nov 19, 2026 is 2.56. In the previous year, P/B (Price-to-Book Ratio) was 2.72 — a change of -5.99% (lower).

P/B

2.56

YoY

-5.99%

Last updated:

P/B (Price-to-Book Ratio) of Biotest is 2024 2.56 . P/B (Price-to-Book Ratio) of Biotest was 2023 2.72 . It decreases by -5.99% lower compared to the previous year.

The Biotest P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2017
3.90 EUR
Jan 1, 2018
2.74 EUR
Jan 1, 2019
2.85 EUR
Jan 1, 2020
3.07 EUR
Jan 1, 2021
3.57 EUR
Jan 1, 2022
3.66 EUR
Jan 1, 2023
2.72 EUR
Jan 1, 2024
2.56 EUR
The Biotest P/B history
YEARP/BYoY
2.56-5.99%
2.72-25.62%
3.66+2.51%
3.57+16.09%
3.07+7.99%
2.85+3.80%
2.74-29.78%
3.90+3.71%
3.77+14.34%
3.29+16.47%
2.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

P/B (Price-to-Book Ratio) of Biotest is 2.56 in 2024.

P/B (Price-to-Book Ratio) of Biotest changed from 2.72 to 2.56, representing a -5.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Biotest since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Biotest with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biotest

All Key Metrics — Biotest